Decisions

Decisions and information for the Parties
The following are links to information or decisions which require the Parties to report to the Secretariat various types of information or require the Secretariat to make available to the Parties that information which may be of interest to them.

Methyl Bromide Related Reporting
Decision XIV/6	Informe sobre la marcha de las actividades del Comité de Opciones Técnicas sobre el Metilbromuro Rapport d’activités du Comité desChoix Techniques pour le Bromure de Méthyle
Decision Ex.I/4 (1) & (2)	Methyl Bromide Alternatives
Decision Ex.I/4(3)	National Management Strategy for Phase-out of Critical Uses of Methyl Bromide
Decision Ex.I/4(7)	Critical Use Nominations and reasons why alternatives are not technically and economically feasible
Decision Ex.I/3(5) Decision XVI/2(4) Decision XVII/9(5)	Application of Criteria in Dec. IX/6 when Licensing, Permitting or Authorizing the use of Methyl Bromide
Other Decisions	Title
Decision XVII/47	Dates of future Montreal Protocol meetings
Paragraph 172 of the report of the 17th MOP	Canadian proposal on guidelines for disclosure of interests for groups such as the TEAP and its Technical Options Committees: Request for comments
Decision XV/5(4)	Plans of action regarding the phase-out of the domestic use of CFC-containing metered-dose inhalers
Decisions XIV/5	Information on inhaler treatments for asthma and COPD that contain CFCs or that do not contain CFCs
Decision XV/3	Obligations of Parties to the Beijing Amendment under Article 4 of the Montreal Protocol with respect to HCFCs
Decisions XIII/5, X/8 and IX/24	New Ozone Depleting Substances that have been reported by the Parties
Decision XII/2(3)	Measures by Parties to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers
Decision X/19(4)	Decisions on Essential Uses: Laboratory and Analytical Uses
Decision X/9	Parties not wishing to receive products and equipment relying on Annex A and B Substances
Decision X/7(2)	Halons Management Strategies Reported by the Parties
Decision IX/19(5)	Transition Strategy to Non-CFC Metered Dose Asthma Inhalers (MDIs) Canada, French Czech Republic European Community, French, Spanish Hungary New Zealand Poland
Decision VI/9(4)	Reclamation Facilities Reported by the Parties